Business Context and Reporting Period
Company: Aastrom Biosciences, Inc. (Note: Input metadata referenced Vericel Corp, but filing text confirms Aastrom Biosciences, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2009
Business Stage: Clinical development stage company focused on autologous cellular therapies for cardiovascular diseases (Cardiac Repair Cells for Dilated Cardiomyopathy and Vascular Repair Cells for Critical Limb Ischemia). The company has never been profitable and relies on equity financing and grants.
Key Financial Metrics
| Metric (in thousands) | Quarter Ended Dec 31, 2009 | Six Months Ended Dec 31, 2009 | Cash Position (Dec 31, 2009) |
|---|---|---|---|
| Total Revenues | $16 | $89 | Cash & Equivalents: $14,739 |
| Net Loss | $(4,575) | $(8,376) | Total Debt: $548 |
| Loss Per Share (Basic/Diluted) | $(0.03) | $(0.05) | Working Capital: $(1,312) |
| R&D Expenses | $3,283 | $6,194 | Accumulated Deficit: $(204,199) |
| SG&A Expenses | $1,316 | $2,262 | Monthly Burn Rate: ~$1.2M |
Material Changes vs. Prior Period
- Revenue Decline: Product sales decreased to $16,000 for the quarter (from $28,000 in the prior year quarter) and $89,000 for the six months (from $55,000 in the prior year six months). Fluctuations are attributed to changes in volume for investigator-sponsored trials in Spain and limited manufacturing supplies.
- Increased Operating Loss: Net loss widened to $4.6 million for the quarter (from $4.1 million) and $8.4 million for the six months (from $8.0 million). This was driven primarily by increased Research and Development (R&D) costs associated with patient recruitment and treatment in the IMPACT-DCM clinical trial.
- SG&A Reduction: Selling, General, and Administrative expenses decreased slightly for the quarter and six-month periods. The six-month decrease included a $279,000 reversal of stock compensation expense related to the forfeiture of options held by the former CEO upon his resignation in December 2009.
- Cash Position: Cash and cash equivalents decreased by $2.3 million from June 30, 2009, to $14.7 million at December 31, 2009, despite raising $5.1 million in equity proceeds during the period.
Guidance, Outlook, and Risks
- Clinical Outlook:
- IMPACT-DCM (Cardiac): The Phase II surgical trial is fully enrolled with 40 patients. Interim data collection is expected in Q3 2010, with results reported in Q4 2010.
- Catheter Trial (Cardiac): A second Phase II trial using catheter-based delivery is expected to begin patient enrollment in Q1 2010.
- RESTORE-CLI (Vascular): The Phase IIb trial for Critical Limb Ischemia has enrolled 82 patients. Interim data analysis is ongoing, with conclusions expected in Q1 2010.
- Liquidity and Capital Needs: Management believes current cash ($14.7M) is sufficient to fund operations through December 31, 2010. However, substantial additional funding is required to complete clinical trials and commercialize products. Monthly cash utilization is projected to increase to approximately $1.4 million for the remainder of fiscal 2010.
- Subsequent Events (Post-Period):
- Public Offering: On January 21, 2010, the company completed a public offering of 52 million units (stock + warrants) at $0.26 per unit, raising approximately $12.4 million in net proceeds.
- Reverse Stock Split: On January 29, 2010, the Board approved a 1-for-8 reverse stock split to regain compliance with NASDAQ minimum bid price requirements. As of the filing date (Feb 9, 2010), this was not yet effective.
- Key Risks:
- Delisting Risk: The company faces potential delisting from NASDAQ if it cannot maintain a minimum bid price of $1.00 per share by March 31, 2010.
- Regulatory Uncertainty: Success depends on FDA and EMEA approvals. Changes in regulatory classification could delay or prevent marketing.
- Capital Constraints: Inability to raise additional funds could force the delay or termination of R&D programs.
Investor Verification Checklist
- Reverse Stock Split Status: Verify if the 1-for-8 reverse stock split has been effected and if the stock price has stabilized above the $1.00 NASDAQ requirement.
- Cash Runway: Confirm the impact of the $12.4 million January 2010 offering on the company's cash runway and ability to fund the 2010 clinical milestones.
- Clinical Trial Data: Monitor the release of interim data for the RESTORE-CLI (Q1 2010) and IMPACT-DCM (Q4 2010) trials for safety and efficacy signals.
- Management Transition: Assess the operational impact of the leadership change (Timothy M. Mayleben replacing George W. Dunbar) on strategic execution.
- Dilution Impact: Review the dilution effects of the recent public offering (52M shares + warrants) and the existing Fusion Capital purchase agreement.